HRP20181454T1 - Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera - Google Patents

Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera

Info

Publication number
HRP20181454T1
HRP20181454T1 HRP20181454TT HRP20181454T HRP20181454T1 HR P20181454 T1 HRP20181454 T1 HR P20181454T1 HR P20181454T T HRP20181454T T HR P20181454TT HR P20181454 T HRP20181454 T HR P20181454T HR P20181454 T1 HRP20181454 T1 HR P20181454T1
Authority
HR
Croatia
Prior art keywords
water
soluble polymer
low content
blood factors
modified blood
Prior art date
Application number
HRP20181454TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Turecek
Juergen Siekmann
Hanspeter Rottensteiner
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of HRP20181454T1 publication Critical patent/HRP20181454T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4846Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HRP20181454TT 2008-10-17 2009-10-16 Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera HRP20181454T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10642408P 2008-10-17 2008-10-17
PCT/US2009/061023 WO2010045568A1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer
EP09752930.9A EP2349342B1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Publications (1)

Publication Number Publication Date
HRP20181454T1 true HRP20181454T1 (hr) 2018-12-14

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181454TT HRP20181454T1 (hr) 2008-10-17 2009-10-16 Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera

Country Status (20)

Country Link
US (4) US20100099616A1 (https=)
EP (3) EP2349342B1 (https=)
JP (2) JP5785872B2 (https=)
KR (2) KR101929641B1 (https=)
AU (1) AU2009305612B2 (https=)
BR (1) BRPI0920259A8 (https=)
CA (1) CA2738679A1 (https=)
CY (1) CY1120921T1 (https=)
DK (1) DK2349342T3 (https=)
ES (1) ES2692172T3 (https=)
HR (1) HRP20181454T1 (https=)
HU (1) HUE039906T2 (https=)
LT (1) LT2349342T (https=)
MX (1) MX2011004085A (https=)
NZ (1) NZ592688A (https=)
PL (1) PL2349342T3 (https=)
PT (1) PT2349342T (https=)
SI (1) SI2349342T1 (https=)
SM (1) SMT201800486T1 (https=)
WO (1) WO2010045568A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106110311A (zh) * 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー/エス 安定化させた第viii因子バリアント
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10238718B2 (en) 2014-08-04 2019-03-26 Csl Limited Factor VIII formulation
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第viii因子の複合体形成能に関する情報の取得方法および試薬キット
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第viii因子に対する寛容を誘導するためのポリペプチド

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
RU2362807C2 (ru) * 2002-06-21 2009-07-27 Ново Нордиск Хелт Кэр Аг Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция
JP2006517400A (ja) 2002-12-19 2006-07-27 ネクター セラピューティクス アラバマ,コーポレイション シアノビリン変異体−ポリマー接合体
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
KR20060003862A (ko) * 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ix 부분의 접합체
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
CA2591852A1 (en) * 2004-12-27 2006-07-06 Baxter International Inc. Polymer-von willebrand factor-conjugates
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1891231A4 (en) * 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2670618C (en) * 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
MX2009007145A (es) * 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.

Also Published As

Publication number Publication date
KR20110071012A (ko) 2011-06-27
EP2349342B1 (en) 2018-06-27
JP5785872B2 (ja) 2015-09-30
PL2349342T3 (pl) 2019-01-31
KR20160103173A (ko) 2016-08-31
DK2349342T3 (en) 2018-10-08
EP3437661A1 (en) 2019-02-06
CA2738679A1 (en) 2010-04-22
NZ592688A (en) 2012-12-21
US20160199503A1 (en) 2016-07-14
PT2349342T (pt) 2018-10-26
JP2012505917A (ja) 2012-03-08
BRPI0920259A2 (pt) 2016-01-05
US20190160178A1 (en) 2019-05-30
EP3620177A1 (en) 2020-03-11
WO2010045568A1 (en) 2010-04-22
BRPI0920259A8 (pt) 2017-09-19
KR101929641B1 (ko) 2018-12-14
ES2692172T3 (es) 2018-11-30
AU2009305612A1 (en) 2010-04-22
MX2011004085A (es) 2011-09-27
US20100099616A1 (en) 2010-04-22
JP2015110676A (ja) 2015-06-18
US20120076749A1 (en) 2012-03-29
SMT201800486T1 (it) 2018-11-09
AU2009305612B2 (en) 2015-05-21
SI2349342T1 (sl) 2018-10-30
HUE039906T2 (hu) 2019-02-28
CY1120921T1 (el) 2019-12-11
LT2349342T (lt) 2018-10-10
EP2349342A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
HRP20181454T1 (hr) Modificirani krvni čimbenici s niskim stupnjem sadržaja u vodi topljivog polimera
BRPI0921822A2 (pt) composição compreendendo polímero e enzima
EP2440221A4 (en) COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ERYTHROCYTE GERMINS
EP2351365A4 (en) MULTIPLE coding CONTENT SUBSTITUTION
BRPI0907575A2 (pt) Ligação de propriedades visuais de gráficos e células dentro de tabelas
EP2249895A4 (en) PLATINUM COBALT BOR BLOOD PUMPING ELEMENT
IL212471A (en) Composition of tissue or fat cells and polyoxomer p188 for use in tissue or fat cell transplantation
EP2310039A4 (en) FGF-9 AND ITS APPLICATION IN CONNECTION WITH BLOOD VESSELS
BRPI0922989A2 (pt) Liberação sustentada de nutrientes in vivo
ZA201305498B (en) Methods and compositions suitable for managing blood glucose in animals
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
GB0705187D0 (en) Improvements in or relating to level measurement
PT2358413T (pt) Dispositivo médico pulsátil concebido para ser utilizado com a cirurgia extracorporal
EP2515915A4 (en) COMPOSITIONS AND METHODS RELATING TO MIRNA IN DIABETIC DRESSES
EP2275940A4 (en) CONTENTS DISPLAY
BRPI0920167A2 (pt) mistura polimérica, copolímero, e, uso de copolímero
BRPI0921791A2 (pt) Composições de polímeros de dihidroxiacetona e usos das mesmas
GB0822283D0 (en) Improvements in or relating to level sensors
GB0818544D0 (en) Improvements in or relating to multi-parameter monitoring
ZA201005875B (en) Use of interleukin-1 conjugates in the treatment of diabetes
BRPI0821700A2 (pt) Métodos para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína em um conjugado polímero-proteína e para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína ou livre em solução
BRPI0914785A2 (pt) preparação farmacêutica em recipientes permeáveis ao vapor de água com estabilidade aperfeiçoada
DK2250179T3 (da) Lecithin-baseret sammensætning og dens anvendelse i fødevarer
PL2291657T3 (pl) Stężenie heterotrimerów blys/april w surowicy oraz zastosowanie w sposobach diagnostycznych
ZA201101137B (en) Prf in cell and tissue culture